Video

Dr. Hamdan on the Potential Use of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

Author(s):

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Most patients with Hodgkin lymphoma are young; however, a subset of patients are over the age of 60, says Hamdan. Historically, these patients have not done very well with doxorubicin, vinblastine, dacarbazine, and vincristine and they experience increased toxicity with the regimen.

At the 2019 ASH Annual Meeting, data from a phase II trial (NCT01716806) showed encouraging responses with the combination of brentuximab vedotin and nivolumab in patients over 60 years with advanced-stage classical Hodgkin lymphoma. Of 19 evaluable patients, 18 had an objective response, 13 had a complete response, and 5 had a partial response. The median duration of response had not been reached at the time of data cutoff. Although the trial was small, the results are encouraging and suggest that the combination may serve as a treatment option for these patients, concludes Hamdan.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center